TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)
Condition: Non-small Cell Lung Cancer Intervention: Drug: TGRX-326 Sponsors: Shenzhen TargetRx, Inc.; Sun Yat-sen University; Tongji Hospital; Sichuan Cancer Hospital and Research Institute; The First Affiliated Hospital of Zhengzhou University; West China Hospital; Zhejiang University; Jilin Provincial Tumor Hospital; Hunan Cance r Hospital; Shandong Cancer Hospital and Institute; Jiangxi Provincial Cancer Hospital; First Hospital of China Medical University; The Affiliated Hospital of Qingdao University; Liaoning Tumor Hospital & I...
Source: ClinicalTrials.gov - July 21, 2023 Category: Research Source Type: clinical trials
Effect of xenon on brain injury, neurological outcome, and survival in patients after aneurysmal subarachnoid hemorrhage —study protocol for a randomized clinical trial
DiscussionDespite improvements in medical technology and advancements in medical science, aSAH mortality and disability rates have remained nearly unchanged for the past 10 years. Therefore, new neuroprotective strategies to attenuate the early and delayed brain injuries after aSAH are needed to reduce morbidity and mortality.Trial registrationClinicalTrials.gov NCT04696523. Registered on 6 January 2021.EudraCT, EudraCT Number: 2019-001542-17. Registered on 8 July 2020. (Source: Trials)
Source: Trials - June 19, 2023 Category: Research Source Type: clinical trials
Clinical Trial to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) B-cell Acute Lymphoblastic Leukemia
Condition: Leukemia Intervention: Biological: IM19 CAR-T cells Sponsor: Beijing Immunochina Medical Science& Technology Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 29, 2022 Category: Research Source Type: clinical trials
